Positivity is the Key – By Des Kelly
&
Pfizer & BioNTech Say Early Tests Show Coronavirus Vaccine More Than 90% Effective
P FIZER
F OR
I N
Z OOM
E ASY
R EST
No prizes offered, for guessing the best
PFIZER’s the one, it passes each test !!.
Kindly note that the above PFIZER Slogan is copyrighted to eLanka – reproduction requires permission (info@eLanka.com.au)
PFIZER MAY HAVE IT
LET’S GET IN, ON THE SCENE,
90% EFFECTIVE,
PROVEN COVID VACCINE,
THE FIRST “GOOD NEWS”
POST BIDEN ELECTION
AMEN !
The news came out very early this morning, Tuesday 10th. November, 2020, proving that even in another Annus Horribilus, as experienced by Her Majesty Queen Elizabeth the 2nd, there is always the hope of at least a skerrick of good news to look forward to. As I always say, Positivity is the Key and to me, Negativity comes in, a bad second.
With the very first “breaking news” on the A.B.C. came the very good POSITIVE news that I have seen in a long time, so naturally, as the spokesperson for eLanka, I decided to share it immediately with the thousands of members of our website.
To be truthful, I always felt that the first successful Vaccine for Covid 19 would come from Australia. However, it now looks like the huge Multinational Pharmaceutical Company Pfizer has beaten us in this particular race, not that it matters of course, because it now looks like America needs this Vaccine more urgently, and Pfizer is headquartered in New York.
Anyway, this is very good news and although there is a further 10% to be accounted for, positivity is the KEY.
Desmond Kelly.
(Editor-in-Chief) eLanka.
Pfizer & BioNTech Say Early Tests Show Coronavirus Vaccine More Than 90% Effective
November 9, 2020
Pfizer Inc. said Monday that results from its most recent human trials on its coronavirus vaccine shows it is more than 90% effective.
The results are based on 94 trial subjects who were infected by the coronavirus and subsequently developed at least one symptom.
Pfizer said it is now on track to ask health regulators for permission to begin distributing and selling the vaccine – which is two shots weeks apart – by the end of the month, if continued trials demonstrate that the vaccine is safe.
The Food and Drug Administration requires a company to monitor at least 50% of a study’s subjects for side effects for a period of two months before making a safety assessment of the vaccine. Pfizers says it is in on track to collect that data by next week, and could apply for FDA emergency authorization soon after that.
The safety and efficacy check of Pfizer’s vaccine was conducted by an independent panel of experts, called a data-safety monitoring committee. They shared their findings with the company on Sunday.
The company’s overall study has required the participation of almost 44,000 individuals in the U.S. and abroad. There have, thus far, been no safety issues. And it is unclear how long the vaccine’s protection against the virus will last.
The FDA has said it won’t authorize a vaccine unless it is at least 50% effective, and wants to see a higher rate of success in an initial set of trial subjects, to ensure its true efficacy.
Pfizer’s vaccine, which was developed with Germany’s BioNTech, was found to be 90% effective seven days following the second shot.
Pfizer’s vaccine is among several that are in late-stage development in the western world, including attempts from Moderna, Johnson & Johnson, and AstraZeneca.
